The stock of Zomedica Pharmaceuticals Corp (CVE:ZOM) hit a new 52-week high and has $4.27 target or 151.00% above today’s $1.70 share price. The 5 months bullish chart indicates low risk for the $161.84 million company. The 1-year high was reported on Nov, 10 by Barchart.com. If the $4.27 price target is reached, the company will be worth $244.38 million more.
The 52-week high event is an important milestone for every stock because it shows very positive momentum and is time when buyers come in. During such notable technical setup, fundamental investors usually stay away and are careful shorting or selling the stock. The stock last traded at $1.7 per share. It is up 6.00% since October 11, 2016 and is uptrending. It has outperformed by 0.35% the S&P500.
More notable recent Zomedica Pharmaceuticals Corp (CVE:ZOM) news were published by: Marketwatch.com which released: “Zomedica Pharmaceuticals Corp. Opens the Market” on May 03, 2016, also Globenewswire.com with their article: “Zomedica Pharmaceuticals Corp. Announces First Quarter 2016 Financial Results …” published on May 26, 2016, Globenewswire.com published: “Zomedica Announces Completion of Qualifying Transaction” on April 27, 2016. More interesting news about Zomedica Pharmaceuticals Corp (CVE:ZOM) were released by: Crainsdetroit.com and their article: “Zomedica aims to specialize in pet pharma” published on August 28, 2016 as well as Globenewswire.com‘s news article titled: “ZoMedica To Complete Listing Transaction on TSX Venture Exchange” with publication date: April 13, 2016.
Zomedica Pharmaceuticals Corp., formerly Wise Oakwood Ventures Inc., is a Canada veterinary pharmaceutical company. The company has a market cap of $161.84 million. The Firm focuses on health and wellness solutions for companion animals, such as canine, feline and equine. It currently has negative earnings. The Firm is engaged in building a portfolio of products comprised of the discovery, development and commercialization of drugs alongside drug delivery systems, devices and diagnostics.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.